Control of Repetitive Movement in Parkinson's Disease

帕金森氏症(PD)在美国影响着100多万人。自愿迁徙到 这些患者的特点是动作迟缓、运动幅度降低(运动迟缓)和缺乏运动能力。 自发的意志性运动(运动不能)。运动迟缓的严重程度随着疾病的加重而增加。 并对生活质量有重大影响。运动迟缓在以下时期最为明显 快速重复动作的表现，当外部线索被移除时，表现会恶化。目的 本项目旨在研究帕金森病患者重复运动功能受损的机制。 以及治疗帕金森病最成功的两种治疗方法，左旋多巴和高频刺激 丘脑底核(STN-DBS)，关于这些机制。第一个具体目标将检查以下各项的影响 重复手指上的运动提示(外部提示与内部提示)、频率(0.8赫兹与2赫兹)和左旋多巴 使用脑电图仪(EEC)记录运动和运动相关的皮质振荡。这个 第二个具体目标将考察相同因素的影响(提示、移动频率和 左旋多巴)对基底节(一组脑深部结构)运动相关活动模式的影响 清醒的帕金森病患者。基底节活动将从植入大脑中的电极记录下来。 帕金森病患者丘脑底核(STN)第三个具体目标是比较左旋多巴的疗效。 与STN-DBS在运动相关的皮质振荡上的对比。皮层运动的高分辨率EEC记录 活动将被用来检验这些治疗是如何影响重复运动的。这些实验将是 首次研究重复运动中运动能力下降的神经生理学基础 帕金森病患者帕金森病模型的运动及左旋多巴和STN-DBS改善运动的皮质机制 在这些运动中。这个项目的长期目标有两个：发展更好的康复 利用促进运动性能的因素并开发出改进的技术 脑深部刺激的实施方法。基底神经节功能障碍与多种疾病有关 包括帕金森氏症在内的神经疾病，影响着美国人口的很大一部分。这个项目是 与公共健康相关，因为这些发现将提供对人类基底节的更好理解 以及它在产生无序运动中的作用，并有助于开发改进的治疗方法。

Parkinson's disease (PD) affects more than a million people in the United States. Voluntary movement in these patients is characterized by slowness and reduced movement amplitude (bradykinesia) and a lack of spontaneous volitional movement (akinesia). The severity of bradykinesia increases with disease progression and has a significant impact on quality of life. Bradykinesia is most evident during the performance of fast repetitive movements and worsened when external cues are removed. The purpose of this project is to examine the mechanisms contributing to impaired repetitive movement in patients with PD and the effects of the two most successful treatments for PD, levodopa and high frequency stimulation of the subthalamic nucleus (STN-DBS), on these mechanisms. The first specific aim will examine the effects of movement cueing (external vs. internal cues), frequency (0.8 Hz vs. 2 Hz) and levodopa on repetitive finger movement and movement-related cortical oscillations recorded using electroencephalography (EEC). The second specific aim will examine the effects of the same factors (cueing, movement frequency and levodopa) on the patterns of movement-related activity in the basal ganglia (a group of deep brain structures) of awake patients with PD. Basal ganglia activity will be recorded from electrodes implanted in the subthalamic nucleus (STN) of patients with PD. The third specific aim will compare the effects of levodopa versus STN-DBS on movement-related cortical oscillations. High-resolution EEC recordings of motor cortical activity will be used to examine how these treatments affect repetitive movement. These experiments will be the first to examine the neurophysiological basis for the deterioration of motor performance during repetitive movements in PD and the cortical mechanisms by which levodopa and STN-DBS improve the performance of these movements. The long-term goals of this project are twofold: to develop improved rehabilitation techniques that take advantage of factors that facilitate movement performance and to develop improved methods for the delivery of deep brain stimulation. Dysfunction of the basal ganglia is implicated in a variety of neurological disorders, including PD, that affect a large segment of the US population. This project is relevant to public health because the findings will provide a better understanding of the human basal ganglia and its role in the production of disordered movement and help to develop improved treatments.